Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial

Puntos clave

• Intradiscal linezolid treatment demonstrates improved outcomes in chronic low back pain.
• Results show significant pain reduction from baseline in the treatment group over 12 weeks.
• Randomised controlled trial, incorporating sham procedures and double-blind design, ensures rigorous testing.
• Highlights the need for further exploration of linezolid's effectiveness in managing Modic changes.